Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins
This observational study is conducted in Europe. The objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those Type 2 diabetic patients who were previously treated with Mixtard® insulins after 6 months of their switch to analog premix insulin NovoMix® 30 therapy.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins|
- HbA1C [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- General conditions (reason of switch, BMI, selected laboratory parameters, quality of care) [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||October 2007|
|Study Completion Date:||April 2008|
|Primary Completion Date:||March 2008 (Final data collection date for primary outcome measure)|
Drug: biphasic insulin aspart 30
The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
Other Name: NovoMix® 30
Please refer to this study by its ClinicalTrials.gov identifier: NCT00657319
|Budapest, Hungary, H-1025|
|Study Director:||Peter Varnai, MD||Novo Nordisk Hungary Ltd.|